In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC.Shots:Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
